Eli Lilly set to launch oral obesity drug by Q2, awaiting US approval

• The oral obesity drug orforglipron could launch as early as the second quarter of 2025 in the U.S.
• Launch is contingent on receiving Food and Drug Administration approval
• Eli Lilly CFO confirmed the company is 'on track' with preparations for the product's market entry

Summary

Key Development:

Eli Lilly is preparing to launch orforglipron, its oral obesity drug, in the United States as early as Q2 2025, pending FDA approval. CFO Lucas Montarce confirmed the timeline at the TD Cowen healthcare conference on March 2.

Product Details:

Orforglipron represents a significant development in the obesity treatment market as an oral medication, distinguishing it from current injectable options. The company states it is "on track" for U.S. regulatory approval and market entry.

Market Implications:

• The launch would expand Eli Lilly's presence in the rapidly growing obesity treatment sector
• An oral formulation could offer competitive advantages over existing injectable therapies by improving patient convenience and compliance
• Q2 launch timing suggests potential revenue contribution in the latter half of 2025
• The obesity drug market has become increasingly lucrative, with major pharmaceutical companies competing for market share

Timeline:

• Expected market entry: Q2 2025 (April-June)
• Contingent on FDA approval

Strategic Context:

This announcement reinforces Eli Lilly's commitment to expanding its obesity treatment portfolio. The oral administration route could differentiate orforglipron in a market currently dominated by injectable medications, potentially capturing patients who prefer non-injection alternatives.

The proximity of the potential launch suggests Eli Lilly is confident in securing regulatory approval, positioning the company to capitalize on strong demand for obesity treatments in the coming months.